You are here

Alnylam

Alnylam boots Type 2 diabetes asset from haunted house

Fierce Biotech

Fri, 11/1/24 - 11:09 am

type 2 diabetes

Alnylam agrees to drop patent lawsuit against Moderna over Covid-19 vaccine

Reuters

Sun, 10/6/24 - 10:50 pm

Moderna Therapeutics

Alnylam’s vutrisiran aces ATTR cardiomyopathy readout

Pharmaphorum

Mon, 06/24/24 - 10:52 am

Ahead of Alnylam's key heart disease readout, experts say Pfizer rival would be hard to displace

Fierce Pharma

Mon, 04/22/24 - 06:01 pm

Alnylam changes to heart drug trial spark doubts, sinking shares

BioPharma Dive

Thu, 02/15/24 - 07:13 pm

clinical trials

Alnylam Publishes Phase III ATTR-CM Data for Patisiran After FDA Rejection

BioSpace

Thu, 10/26/23 - 10:39 am

clinical trials

ATTR with cardiomyopathy

Interest in RNA Editing Accelerates as Therapies Approach the Clinic

BioSpace

Wed, 10/18/23 - 11:37 am

Shape Therapeutics

ProQR Therapeutics

Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future

Pharma Voice

Thu, 10/12/23 - 05:32 pm

Yvonne Greenstreet

FDA denies expanded approval for Alnylam RNA drug

BioPharma Dive

Mon, 10/9/23 - 10:15 am

ATTR amyloidosis

With FDA nod for rare disease drug Rivfloza, Novo Nordisk eyes showdown with Alnylam

Fierce Pharma

Mon, 10/2/23 - 06:36 pm

primary hyperoxaluria type 1

Pfizer's 'entrenched' tafamidis franchise will be tough to challenge for Alnylam, BridgeBio: analysts

Fierce Pharma

Mon, 09/18/23 - 08:01 pm

clinical trials

Despite FDA doubts, Alnylam wins expert backing for Onpattro expansion into rare heart disease

Fierce Pharma

Thu, 09/14/23 - 09:59 am

FDA Questions Efficacy of Alnylam’s Drug in ATTR-CM Ahead of Adcomm Meeting

BioSpace

Tue, 09/12/23 - 07:06 pm

Roche Sees Return on $310M Investment with Alnylam’s Phase II Hypertension Win

BioSpace

Thu, 09/7/23 - 10:49 pm

clinical trials

Agios and Alnylam sign agreement for siRNA candidate

Pharmaceutical Business Review

Fri, 08/4/23 - 12:09 pm

Agios Pharmaceuticals

polycythemia vera

Roche, Alnylam Ink Potential $2.8B RNAi Partnership for Hypertension

BioSpace

Mon, 07/24/23 - 11:29 am

AAIC: First Clinical Data from an RNAi Therapeutic for Alzheimer’s Continue to Impress

BioSpace

Tue, 07/18/23 - 11:55 am

Alzheimer's disease

clinical trials

Alnylam and Regeneron report updated positive Phase I results of Alzheimer’s drug

Clinical Trials Arena

Mon, 07/17/23 - 08:41 am

clinical trials

Alzheimer's disease

5 FDA decisions to watch in the third quarter

BioPharma Dive

Mon, 06/26/23 - 10:04 am

SAGE Therapeutics

Pages